Byotrol Regulatory News (BYOT)

Byotrol Plc

("Byotrol" or the "Group")

Exercise of Options and Total Voting Rights

Byotrol plc (AIM: BYOT), the anti-microbial technology company, announces that it has allotted a total of 3,381,000 new ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") following the exercise of options by certain employees, all of whom are below Board level.

Application has been made for the 3,381,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 26 January 2021.

After Admission, the total number of Ordinary Shares in issue will be 446,530,405 and the total number of voting rights will therefore be 446,530,405. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information contact:

Notes to editors

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

For more information, please go to byotrol.co.uk